title: [Connection between uterine myomas and biochemical screening results in the first and second trimester of pregnancy].
abstract: OBJECTIVE
  Uterine myomas may change the concentrations of the screening serum markers and therefore alter the risk calculation of the fetal chromosomal abnormalities. An increased risk leads to invasive diagnostics procedures which in these cases can often be technically difficult due to the presence of myomas.
  
  
  OBJECTIVE
  The aim of this study was to assess the influence of uterine myomas on the first and second trimester serum markers concentrations and, possibly on the test results.
  
  
  METHODS
  The study group consisted of 127 women between 11 and 20 weeks of normal singleton pregnancy. In each case uterine myomas were diagnosed--over 20 mm in the diameter and located in the uterine wall. 77 patients underwent the first trimester screening (PAPP-A & free beta-hCG) and 50 patients had the second trimester screening (triple test). The control group consisted of 1020 women between 11 and 20 weeks of normal singleton pregnancy without uterine myomas. Delfia Xpress analyser was used for the serum markers estimations. All pregnant women delivered normal healthy babies.
  
  
  RESULTS
  In the first trimester group the PAPP-A serum concentrations were not different from the controls while the mean median concentration of free beta-hCG were significant higher--1.43 MoM. In the second trimester group the following mean median values were observed: no significance for the AFP--1.18 MoM and estriol--1.29 MoM and significantly higher mean median value for the free beta-hCG--2.01 MoM.
  
  
  CONCLUSIONS
  1. The presence of the uterine myomas is connected with the increased maternal serum concentration of the beta-hCG, particularly in the second trimester. 2. The uterine myomas may lead to the increased rate of the false positive results of the prenatal screening test, especially the triple test.
authors.affiliation: Klinika Medycyny Płodu i Ginekologii I Katedry Ginekologii i Połoznictwa Uniwersytetu Medycznego w Łodzi. piotr.sieroszewski@umed.lodz.pl
authors.forename: Piotr
authors.initials: P
authors.lastname: Sieroszewski
authors.forename: Łukasz
authors.initials: Ł
authors.lastname: Bober
authors.forename: Dorota
authors.initials: D
authors.lastname: Wierzbicka
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Baś-Budecka
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Perenc
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000032:analysis*; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000097:blood* / Q000175:diagnosis; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000097:blood* / Q000175:diagnosis; D011261:Pregnancy Trimester, First / Q000097:blood; D011262:Pregnancy Trimester, Second / Q000097:blood; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis*; D011296:Prenatal Diagnosis / Q000379:methods; D012016:Reference Values; D014594:Uterine Neoplasms / Q000097:blood* / Q000175:diagnosis; D055815:Young Adult
chemical_list: D015415:Biomarkers; D018997:Chorionic Gonadotropin, beta Subunit, Human; D011266:Pregnancy-Associated Plasma Protein-A